Skip to content
DataLookout
Menu

Gilead Sciences clinical trial pipeline

Get alerts when Gilead Sciences's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

17 trials changed in the last 30 days: 1 stopped, 7 with notable changes, 9 with minor changes only.

  1. Stopped: WONDERS1 · Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy · HIV-1 Who Are Virologically Suppressed Trial terminated Gilead SciencesPhase 2/3 NCT06544733
  2. Notable: HERMOSA-2 · KITE-363 · Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment Primary and study completion pushed from Jun 2029 to Dec 2031 Kite, A Gilead CompanyPhase 1 NCT07304154
  3. Notable: ZUMA-24 · Axicabtagene Ciloleucel Given With Steroids · Relapsed Or Refractory Large B-Cell Lymphoma Results posted: Nov 12, 2026 Kite, A Gilead CompanyPhase 2 NCT05459571
  4. Minor: GS-2426 · Advanced Solid Tumors Trial sites expanded: 4 → 8 locations Gilead SciencesPhase 1 NCT07601243
  5. Minor: GS-0201 Alone and in Combination · Advanced Solid Tumors Trial sites expanded: 8 → 14 locations Gilead SciencesPhase 1 NCT06167317
  6. Minor: Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy · Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas Enrollment closed, study ongoing Gilead SciencesPhase 2 NCT07546812
  7. Minor: Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment Trial sites expanded: 16 → 21 locations Gilead SciencesPhase 2/3 NCT07708727
  8. Minor: GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed · HIV-1 Trial sites expanded: 55 → 59 locations Gilead SciencesPhase 2 NCT07645287
  9. Notable: ARTISTRY-2 · Bictegravir/Lenacapavir Versus Current Therapy · HIV-1 Who Are Successfully Treated With Biktarvy Results posted: Nov 5, 2026 Gilead SciencesPhase 3 NCT06333808
  10. Minor: NAPISTAR1-01 · FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 · PROC or r/r Adenocarcinoma NSCLC Enrollment increased: 250 → 334 participants Gilead SciencesPhase 1/2 NCT06303505
  11. Minor: PALISADES-1 · KITE-363 or KITE-753 · Relapsed and/or Refractory B-cell Lymphoma Enrollment closed, study ongoing Kite, A Gilead CompanyPhase 1/2 NCT04989803
  12. Notable: Seladelpar and Cilofexor · Primary Biliary Cholangitis Recruitment opened Gilead SciencesPhase 2 NCT07841977
  13. Minor: KITE-753 Versus Axicabtagene Ciloleucel · Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy Enrollment closed, study ongoing Kite, A Gilead CompanyPhase 3 NCT07479797
  14. Notable: Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth · HIV-1 With Undetectable Virus Levels Recruitment opened Gilead SciencesPhase 2 NCT07841990
  15. Notable: Anitocabtagene Autoleucel · Non-Oncology Plasma Cell-Related Diseases Primary and study completion dates pushed to Oct 2028 Kite, A Gilead CompanyPhase 1 NCT06626919
  16. Notable: ARTISTRY-1 · Bictegravir/Lenacapavir Versus Current Therapy · HIV-1 Who Are Successfully Treated With a Complicated Regimen Results posted: Oct 21, 2026 Gilead SciencesPhase 2/3 NCT05502341
  17. Minor: PROPEL · Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention Trial sites expanded: 39 → 44 locations Gilead SciencesNot specified NCT07473778
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-03 NCT07912996 Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With… Phase 2 Not Yet Recruiting
2026-11-02 NCT07908446 Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People… Phase 4 Not Yet Recruiting
2026-10-29 NCT07903506 To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell… Phase 3 Not Yet Recruiting
2026-10-21 NCT07887672 A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of… Phase 3 Not Yet Recruiting

Active trials by phase

Phase 1
20
Phase 1/2
8
Phase 2
26
Phase 2/3
6
Phase 3
26
Phase 4
2
Not charted: 2 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 28

Get alerts when Gilead Sciences's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free